ES2957692T3 - Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP - Google Patents

Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP Download PDF

Info

Publication number
ES2957692T3
ES2957692T3 ES19821320T ES19821320T ES2957692T3 ES 2957692 T3 ES2957692 T3 ES 2957692T3 ES 19821320 T ES19821320 T ES 19821320T ES 19821320 T ES19821320 T ES 19821320T ES 2957692 T3 ES2957692 T3 ES 2957692T3
Authority
ES
Spain
Prior art keywords
alkyl
ring
aryl
halo
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19821320T
Other languages
English (en)
Spanish (es)
Inventor
Jason Katz
William Roush
Hans Seidel
Dong-Ming Shen
Shankar Venkatraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2957692T3 publication Critical patent/ES2957692T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES19821320T 2018-11-13 2019-11-11 Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP Active ES2957692T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862760244P 2018-11-13 2018-11-13
US201862760279P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US201962795373P 2019-01-22 2019-01-22
US201962796356P 2019-01-24 2019-01-24
US201962796361P 2019-01-24 2019-01-24
PCT/US2019/060775 WO2020102100A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (1)

Publication Number Publication Date
ES2957692T3 true ES2957692T3 (es) 2024-01-24

Family

ID=68916531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19821320T Active ES2957692T3 (es) 2018-11-13 2019-11-11 Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP

Country Status (6)

Country Link
US (1) US12134611B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880666B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022506898A (cg-RX-API-DMAC7.html)
CN (1) CN113166081A (cg-RX-API-DMAC7.html)
ES (1) ES2957692T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020102100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN117185965B (zh) * 2023-09-18 2024-10-11 安徽金桐精细化学有限公司 一种磺酸基丙烯酸盐复配表面活性剂的制备方法
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof
CN119775202A (zh) * 2024-12-31 2025-04-08 河南旭瑞新材料科技有限公司 一种2-巯基烟酰甘氨酸的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
CA2085297A1 (en) 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
PL344004A1 (en) 1998-05-05 2001-09-10 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
US11370763B2 (en) 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PY1975819A (es) 2018-09-13 2020-04-09 Bayer Ag Derivados heterocíclicos como plaguicidas.-
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Also Published As

Publication number Publication date
EP3880666B1 (en) 2023-06-28
JP2022506898A (ja) 2022-01-17
WO2020102100A1 (en) 2020-05-22
WO2020102100A9 (en) 2022-01-06
US12134611B2 (en) 2024-11-05
US20230024859A1 (en) 2023-01-26
CN113166081A (zh) 2021-07-23
EP3880666A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
ES2949404T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
JP7730759B2 (ja) Nlrp活性に関連する病態を治療するための化合物及び組成物
CN112584899A (zh) Nlrp调节剂
EP3880666B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
EP3870565A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
EP3914585A1 (en) Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
EP3914583A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
WO2020010140A1 (en) Nlrp modulators
EP3880658A1 (en) The compounds and compositions for treating conditions associated with nlrp activity
ES2974842T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
HK40103462A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570B (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570A (en) Compounds and compositions for treating conditions associated with nlrp activity
EA042417B1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью nlrp